CD8A and neoplasm: Dynamic response biomarkers—such as post-treatment increases in CD8+ tumor-infiltrating lymphocytes (TILs) and PD-L1 expression, as well as the rate of circulating tumor DNA (ctDNA) clearance—will facilitate real-time efficacy assessment and dose adjustment (36).